Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [11]

Axel Grothey; Daniel Sargent

doi:10.1200/JCO.2005.04.4792

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [11]

Axel Grothey, Daniel Sargent

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	9441-9442
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	23
Issue number	36
DOIs	https://doi.org/10.1200/JCO.2005.04.4792
State	Published - Dec 1 2005

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2005.04.4792

Cite this

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [11]. / Grothey, Axel; Sargent, Daniel.
In: Journal of Clinical Oncology, Vol. 23, No. 36, 01.12.2005, p. 9441-9442.

Research output: Contribution to journal › Letter › peer-review

@article{4a13c0c1fd6e4080be5bfc750bccd25b,

title = "Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [11]",

author = "Axel Grothey and Daniel Sargent",

year = "2005",

month = dec,

day = "1",

doi = "10.1200/JCO.2005.04.4792",

language = "English (US)",

volume = "23",

pages = "9441--9442",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "36",

}

TY - JOUR

T1 - Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [11]

AU - Grothey, Axel

AU - Sargent, Daniel

PY - 2005/12/1

Y1 - 2005/12/1

UR - http://www.scopus.com/inward/record.url?scp=33644825856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644825856&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.04.4792

DO - 10.1200/JCO.2005.04.4792

M3 - Letter

C2 - 16361649

AN - SCOPUS:33644825856

SN - 0732-183X

VL - 23

SP - 9441

EP - 9442

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 36

ER -

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [11]

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this